PK Med, created by Truffle Capital in July 2019, focuses on the development of therapeutic products delivered directly to pathological areas to address unmet medical needs with high societal stakes such as inflammatory joint diseases or tissue regeneration.Innovative implants are developed from 3D biomaterial structures and drug delivery technologies
Two programs are conducted in parallel:
- Local pain treatments in joint diseases
- Tissue regeneration from 3D biopolymer structures
Synoptical view
- First investment date
- 2019
